Cat. No. |
Product Name |
Information |
PC-38555 |
ACAi-028
HIV-1 capsid inhibitor
|
ACAi-028 is a small molecule inhibiting HIV-1 replication (EC50=0.55 uM) that targets a hydrophobic pocket in the N-terminal domain of capsid (CA-NTD). |
PC-38494 |
SRI-41897
HIV-1 Vpu inhibitor
|
SRI-41897 is a specific small molecule inhibitor of HIV-1 N-terminal region of NL4-3 Vpu (HIV-1 NL4-3 Vpu) with EC50 of 4.4 uM in the GaLV inhibition assays. |
PC-38387 |
Elunonavir
HIV inhibitor
|
Elunonavir is an azapeptide atazanavir analogs useful for treating HIV infections. |
PC-73411 |
Claficapavir
HIV-1 inhibitor
|
Claficapavir (A1752) is a specific small molecule inhibitor of HIV-1 nucleocapsid protein (Kd=20 nM), shows a strong antiviral efficacy with IC50 of 1 uM. |
PC-73246 |
NBD-14273
HIV entry inhibitor
|
NBD-14273 is a CD4-mimetic, small-molecule HIV-1 entry inhibitor with IC50 of 0.13 uM. |
PC-72432 |
SBI-0637142
Latency-reversing agent
|
SBI-0637142 is a potent Smac mimetic that preferentially targets BIRC2, latency-reversing agent (LRA), specifically and potently promote HIV-1 latency reversal activity. |
PC-72431 |
Ciapavir
Latency-reversing agent
|
Ciapavir (SBI-0953294, cIAP1 antagonist for viral reactivation) is a bivalent, next-generation, Smac mimetic and antagonist of cIAP1 as latency-reversing agent (LRA), specifically and potently promote HIV-1 latency reversal activity both in vivo. |
PC-36158 |
HIV-1 inhibitor 5b
|
HIV-1 inhibitor 5b is a novel anti-HIV-1 compound that inhibits HIV-1 JR-CSF with EC50 of 1 nM without significant cytotoxicity (CC50>20 uM), also shows potency against NRTI- and NNRTI-resistant HIV-1 (EC50=1-3 nM). |
PC-35229 |
1E7-03
|
1E7-03 is a small molecule targeting the RVxF interacting site on PP1, inhibits HIV-1, Ebolavirus (EBOV), and Venezuelan equine encephalitis virus (VEEV, EC50=0.6 uM). |
PC-35228 |
BNM-III-170
|
BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo. |
PC-35227 |
BNM-III-170 trifluoroacetate
|
BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo. |
PC-35158 |
IMB-301
|
IMB-301 (NSC 301209) is a small molecule inhibitor that target the binding interface of the HIV-1 Vif/hA3G complex, inhibits the replication of HIV-1 in H9 cells (IC50=8.63 uM). |